PR Newswire

Foresee Pharmaceuticals Announces Completion of Last Patient Visit in Registration Phase 3 Study of LMIS 25 mg (fp-001) for the Treatment of Advanced Prostate Cancer

TAIPEI, Taiwan, Nov. 26, 2018 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) today announced that all patients had completed participation in its Phase 3, multinational, multicenter ...
Medindia

Foresee Pharmaceuticals Announces Successful Topline Results from Phase 3 Registration Study of LMIS 25 mg in Prostate Cancer

TAIPEI, Taiwan, February 21, 2019 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announced today the topline results of FP-001 LMIS (Leuprolide Mesylate Injectable ...